retatrutide good for liver significantly improved health in patients with non-alcoholic fatty liver disease 💉 Retatrutide — The Future

Retatrutide is currently in clinical trials and not yet approved by Health Canada or the FDA for general use.

Finally, the combination of a GLP-1 receptor agonist and amylin agonism by cagrilintide/semaglutide is currently under investigation (Table 1)

Retatrutide is an investigational triple hormone receptor agonist (targeting GIP, GLP-1, and glucagon receptors) that has not received marketing authorisation from the MHRA or EMA

10.1371/journal.pone.0189060 289

It is important to note that retatrutide has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed treatment in the United Kingdom at this time

Weight loss was progressive and sustained, with no evidence of plateauing at higher doses within the study timeframe